Eledon Pharmaceuticals Inc
ELDN
Get informed when a big investor buys or sells
+ FollowMarket Cap$230.8M
Close$
$0.27
93.3% downside
Current Fair Value
93.3% downsideOvervalued by 93.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $230.80 Million |
|---|---|
| Enterprise Value | $225.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.56 |
| Beta | 0.96 |
| Outstanding Shares | 112,424,211 |
Return
| Return on Equity | -77.79% |
|---|---|
| Return on Assets | -53.28% |
| Return on Invested Capital | -63.70% |
Valuation & Multiples
| P/E Ratio | -4.43 |
|---|---|
| PEG | -0.88 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.65 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.14%▼ 56.36% |
|---|---|
| Total Invested | $610,019▼ 99.54% |
| Investors Holding | 8▼ 115.00% |
ESG Score
No data
About Eledon Pharmaceuticals Inc
10 employees
CEO: Gregory Flesher Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-bas...